RxDoctor Payments Data

Hana Saleh, MD

Internal Medicine · Hemet, CANPI 1275844912

Payments from drug & device makers

$2,545in general payments, 2019–2025

Across 138 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$456
  • Novartis$292
  • GSK$187
  • Lilly USA, LLC$135
  • Neurocrine Biosciences, Inc.$122
  • Boehringer Ingelheim$121
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$2,545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,545 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$93,418
Medicare patients
135
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$176,955
OzempicSemaglutide71$67,077
ProliaDenosumab38$64,664
JardianceEmpagliflozin29$43,902
Dupixent PenDupilumab11$42,053
XareltoRivaroxaban27$37,353
MyrbetriqMirabegron24$27,367
FarxigaDapagliflozin Propanediol19$26,788
JanuviaSitagliptin Phosphate22$20,875
TrulicityDulaglutide16$19,315
LinzessLinaclotide23$18,540
MounjaroTirzepatide16$16,087
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,528
Tresiba Flextouch U-100Insulin Degludec26$13,810
JanumetSitagliptin Phos/Metformin Hcl18$13,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$176,955145 claims
Novo NordiskOzempic$87$67,07771 claims
AmgenProlia$456$64,66438 claims
Boehringer IngelheimJardiance$121$43,90229 claims
Johnson & JohnsonXarelto$96$37,35327 claims
Lilly USA, LLCTrulicity, Mounjaro$135$35,40332 claims
MerckJanuvia, Janumet$28$34,59840 claims
AstraZenecaFarxiga, Symbicort$65$29,66731 claims
Astellas Pharma US IncMyrbetriq$51$27,36724 claims
AbbVieLinzess, Synthroid$40$22,04490 claims
GSKTrelegy Ellipta, Anoro Ellipta$187$21,82928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →